{"downloaded": true, "htmlmade": false, "full": {"id": "29437791", "source": "MED", "pmid": "29437791", "pmcid": "PMC5932089", "fullTextIdList": {"fullTextId": "PMC5932089"}, "doi": "10.1158/1078-0432.ccr-17-2282", "title": "A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.", "authorString": "Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL.", "authorList": {"author": [{"fullName": "Pardee TS", "firstName": "Timothy S", "lastName": "Pardee", "initials": "TS", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina. tspardee@wakehealth.edu."}, {"affiliation": "Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}, {"affiliation": "Rafael Pharmaceuticals Inc, Cranbury, New Jersey."}]}}, {"fullName": "Anderson RG", "firstName": "Rebecca G", "lastName": "Anderson", "initials": "RG", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}, {"affiliation": "Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}]}}, {"fullName": "Pladna KM", "firstName": "Kristin M", "lastName": "Pladna", "initials": "KM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Isom S", "firstName": "Scott", "lastName": "Isom", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistical Sciences, Wake Forest Public Health Sciences, Winston-Salem, North Carolina."}}}, {"fullName": "Ghiraldeli LP", "firstName": "Lais P", "lastName": "Ghiraldeli", "initials": "LP", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Miller LD", "firstName": "Lance D", "lastName": "Miller", "initials": "LD", "authorId": {"@type": "ORCID", "#text": "0000-0003-3799-2528"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Chou JW", "firstName": "Jeff W", "lastName": "Chou", "initials": "JW", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Department of Biostatistical Sciences, Wake Forest Public Health Sciences, Winston-Salem, North Carolina."}, {"affiliation": "Biostatistics Core, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}]}}, {"fullName": "Jin G", "firstName": "Guangxu", "lastName": "Jin", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Biostatistics Core, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Zhang W", "firstName": "Wei", "lastName": "Zhang", "initials": "W", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Ellis LR", "firstName": "Leslie R", "lastName": "Ellis", "initials": "LR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Berenzon D", "firstName": "Dmitriy", "lastName": "Berenzon", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Howard DS", "firstName": "Dianna S", "lastName": "Howard", "initials": "DS", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Hurd DD", "firstName": "David D", "lastName": "Hurd", "initials": "DD", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Manuel M", "firstName": "Megan", "lastName": "Manuel", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Dralle S", "firstName": "Sarah", "lastName": "Dralle", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Lyerly S", "firstName": "Susan", "lastName": "Lyerly", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}, {"fullName": "Powell BL", "firstName": "Bayard L", "lastName": "Powell", "initials": "BL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-3799-2528"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "9", "volume": "24", "journalIssueId": "2678203", "dateOfPublication": "2018 May", "monthOfPublication": "5", "yearOfPublication": "2018", "printPublicationDate": "2018-05-01", "journal": {"title": "Clinical cancer research : an official journal of the American Association for Cancer Research", "ISOAbbreviation": "Clin Cancer Res", "medlineAbbreviation": "Clin Cancer Res", "NLMid": "9502500", "ISSN": "1078-0432", "ESSN": "1557-3265"}}, "pubYear": "2018", "pageInfo": "2060-2073", "abstractText": "<b>Purpose:</b> CPI-613, a lipoate analogue that inhibits pyruvate dehydrogenase (PDH) and \u03b1-ketogluterate dehydrogenase (KGDH), has activity in patients with myeloid malignancies. This study explored the role of mitochondrial metabolism in chemotherapy response and determined the MTD, efficacy, and safety of CPI-613 combined with high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia.<b>Experimental Design:</b> The role of mitochondrial response to chemotherapy was assessed in cell lines and animal models. A phase I study of CPI-613 plus cytarabine and mitoxantrone was conducted in patients with relapsed or refractory AML.<b>Results:</b> Exposure to chemotherapy induced mitochondrial oxygen consumption that depended on PDH. CPI-613 sensitized AML cells to chemotherapy indicating that mitochondrial metabolism is a source of resistance. Loss of p53 did not alter response to CPI-613. The phase I study enrolled 67 patients and 62 were evaluable for response. The overall response rate was 50% (26CR+5CRi/62). Median survival was 6.7 months. In patients over 60 years old, the CR/CRi rate was 47% (15/32) with a median survival of 6.9 months. The response rate for patients with poor-risk cytogenetics also was encouraging with 46% (11/24 patients) achieving a CR or CRi. RNA sequencing analysis of a subset of baseline bone marrow samples revealed a gene expression signature consistent with the presence of B cells in the pretreatment marrow of responders.<b>Conclusions:</b> The addition of CPI-613 to chemotherapy is a promising approach in older patients and those with poor-risk cytogenetics. <i>Clin Cancer Res; 24(9); 2060-73. \u00a92018 AACR</i>.", "affiliation": "Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, North Carolina. tspardee@wakehealth.edu.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["research-article", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "P30 CA012197", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "UL1 TR001420", "agency": "NCATS NIH HHS", "acronym": "TR", "orderIn": "0"}, {"grantId": "R01 CA197991", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Cell Line"}, {"majorTopic_YN": "N", "descriptorName": "Mitochondria", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Bone Marrow", "meshQualifierList": {"meshQualifier": {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Animals"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Mice"}, {"majorTopic_YN": "N", "descriptorName": "Recurrence"}, {"majorTopic_YN": "N", "descriptorName": "Sulfides", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Caprylates", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Mitoxantrone", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cytarabine", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Biopsy"}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Staging"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Retreatment"}, {"majorTopic_YN": "N", "descriptorName": "Cell Respiration", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Oxygen Consumption", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Drug Resistance, Neoplasm"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Myeloid, Acute", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Grading"}, {"majorTopic_YN": "N", "descriptorName": "Biomarkers"}]}, "chemicalList": {"chemical": [{"name": "Caprylates", "registryNumber": "0"}, {"name": "Sulfides", "registryNumber": "0"}, {"name": "Cytarabine", "registryNumber": "04079A1RDZ"}, {"name": "Mitoxantrone", "registryNumber": "BZ114NVM5P"}, {"name": "Biomarkers", "registryNumber": "0"}, {"name": "devimistat", "registryNumber": "E76113IR49"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.CCR-17-2282"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5932089"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5932089?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1158/1078-0432.ccr-17-2282"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "21", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS941138", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-11-14", "dateOfCreation": "2018-02-14", "firstIndexDate": "2018-02-14", "fullTextReceivedDate": "2020-10-09", "dateOfRevision": "2021-04-07", "electronicPublicationDate": "2018-02-06", "firstPublicationDate": "2018-02-06", "embargoDate": "2019-05-01"}, "abstract": "<b>Purpose:</b> CPI-613, a lipoate analogue that inhibits pyruvate dehydrogenase (PDH) and \u03b1-ketogluterate dehydrogenase (KGDH), has activity in patients with myeloid malignancies. This study explored the role of mitochondrial metabolism in chemotherapy response and determined the MTD, efficacy, and safety of CPI-613 combined with high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia.<b>Experimental Design:</b> The role of mitochondrial response to chemotherapy was assessed in cell lines and animal models. A phase I study of CPI-613 plus cytarabine and mitoxantrone was conducted in patients with relapsed or refractory AML.<b>Results:</b> Exposure to chemotherapy induced mitochondrial oxygen consumption that depended on PDH. CPI-613 sensitized AML cells to chemotherapy indicating that mitochondrial metabolism is a source of resistance. Loss of p53 did not alter response to CPI-613. The phase I study enrolled 67 patients and 62 were evaluable for response. The overall response rate was 50% (26CR+5CRi/62). Median survival was 6.7 months. In patients over 60 years old, the CR/CRi rate was 47% (15/32) with a median survival of 6.9 months. The response rate for patients with poor-risk cytogenetics also was encouraging with 46% (11/24 patients) achieving a CR or CRi. RNA sequencing analysis of a subset of baseline bone marrow samples revealed a gene expression signature consistent with the presence of B cells in the pretreatment marrow of responders.<b>Conclusions:</b> The addition of CPI-613 to chemotherapy is a promising approach in older patients and those with poor-risk cytogenetics. <i>Clin Cancer Res; 24(9); 2060-73. \u00a92018 AACR</i>.", "journaltitle": "Clinical cancer research : an official journal of the American Association for Cancer Research", "authorinfo": ["Pardee TS", "Anderson RG", "Pladna KM", "Isom S", "Ghiraldeli LP", "Miller LD", "Chou JW", "Jin G", "Zhang W", "Ellis LR", "Berenzon D", "Howard DS", "Hurd DD", "Manuel M", "Dralle S", "Lyerly S", "Powell BL"], "title": "A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia."}